Panobinostat-[d4]

Category	Human immunodeficiency Virus (HIV)
CAS	1185237-51-7
Description	Panobinostat-[d4], is the labelled analogue of Panobinostat. Panobinostat is a drug for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor.

Quotation Now

Synonyms	Panobinostat D4
IUPAC Name	(E)-N-hydroxy-3-[4-[[2-(4,5,6,7-tetradeuterio-2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
Molecular Weight	353.45
Molecular Formula	C21H19D4N3O2
Canonical SMILES	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO
InChI	InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+/i2D,3D,4D,5D
InChIKey	FPOHNWQLNRZRFC-KRLNZIKCSA-N
Purity	>98%
Solubility	Soluble in DMSO, Methanol
Appearance	Solid
Storage	Store at 2-8°C
Complexity	474
Exact Mass	353.20413397
In Vitro	Panobinosta (LBH589) induces Apoptosis of both MOLT-4 and Reh cells in a time- and dose-dependent manner. Panobinosta treatment results in histone (H3K9 and H4K8) hyperacetylation and regulation of cell-cycle control genes in Reh cells. Panobinostat exhibites potent antiproliferative activity in human NSCLC cell lines with the IC50 ranging from 5 to 100 nM.
In Vivo	Panobinosta (10, 20 mg/kg, i.p.) significantly slows tumor growth derived from Meso and NSCLC cells in vivo models. Panobinosta markedly increases acetylation of histone H3 and H4 of H69 human SCLC cells harvest from SCID mice. Panobinostat (5, 10 and 20 mg/kg i.p.) demonstrates a clear benefit of decreased tumor burden, significantly improves TTE and reduces bone density loss in a disseminated multiple myeloma mouse model.
Target	HDAC; Autophagy; HIV; Apoptosis
XLogP3-AA	3